Thu, Jul 24, 2014, 9:44 AM EDT - U.S. Markets close in 6 hrs 16 mins

Recent

% | $
Click the to save as a favorite.

Affymax, Inc. (AFFY) Message Board

  • jagan1961 jagan1961 Oct 19, 2013 4:44 PM Flag

    Look at the side effects and deaths of another form of Epogen - Procreit!

    This is just actual deaths. If you consider per GEEWEEPEE type analysis - ALL SUSPECTED DEATHS multiply this by 10- 10 X on an average. What a filthy fraudster going around posting false info on AFFY!

    MOST COMMON PROCRIT ADVERSE EVENTS REPORTED TO THE FDA
    What are the most common Procrit adverse events reported to the FDA?

    Aplasia Pure Red Cell
    537 (3.4%)
    Haemoglobin Decreased
    461 (2.92%)
    Therapeutic Response Decreased
    460 (2.91%)
    Anaemia
    338 (2.14%)
    Fatigue
    321 (2.03%)
    Death
    318 (2.01%)
    Drug Ineffective
    281 (1.78%)
    Asthenia
    241 (1.53%)
    Nausea
    194 (1.23%)
    Dyspnoea
    192 (1.22%)
    Oedema Peripheral
    185 (1.17%)
    Show More Show More
    ExportShare/Embed GraphExport Export Data

    This graph shows the top adverse events submitted to the FDA for Procrit, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Procrit is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

    ADVERSE EVENT CATEGORIES FOR PROCRIT
    What are the most common Procrit adverse events reported to the FDA?

    Hematology Investigations
    1310 (8.29%)
    Anemias Nonhemolytic And Marrow Dep...
    1069 (6.76%)
    Therapeutic And Nontherapeutic Effe...
    853 (5.4%)
    Epidermal And Dermal Conditions
    533 (3.37%)
    Neurological
    514 (3.25%)
    Gastrointestinal Signs
    449 (2.84%)
    Infections - Pathogen Unspecified
    419 (2.65%)
    Musculoskeletal And Connective Tiss...
    391 (2.47%)
    Respiratory
    368 (2.33%)
    Fatal Outcomes
    319 (2.02%)
    Administration Site Reactions
    312 (1.97%)
    Show More Show More
    ExportShare/Embed Graph Export Export Data

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Jagan labelling me a fraudster is like the pot calling the kettle black.

    • This is a favorite AFFY pumper form of misrepresentation. Jagan, and other AFFY pumpers take an ESA, such as Procrit, and publish the "PERCENTAGE OF THE ADVERSE EVENT TO ALL ADVERSE EVENTS REPORTED FOR THE DRUG." They then use those percentages against the Omontys PEARL statistics or the Omontys anaphylaxis death/adverse event percentages reported to say see Omontys isn't so bad. The problem is the the Omontys PEARL statistics and Omontys anaphylaxis death/adverse event percentages are based on the PERCENTAGE OF THE ADVERSE EVENT TO THE NUMBER OF PATIENTS TREATED WITH THE DRUG.

      I am astonished to the lengths the AFFY long pumpers go to mislead others into investing in AFFY whose shares, on a fundamental analysis, are worth very little and are probably worthless inasmuch as AFFY is facing bankruptcy as it consistently warns in its SEC filings. I am also astonished when I point out the misleading example of posts similar to jagan's post and I am villified for pointing out the misrepresentation. For another example see the post by declaes on Sept 19 entitled "Don't forget why you bought AFFY... Much worse product are at the market at this time..." and pay attention to my reply to that post. There declaes did the same kind of misrepresentation with Aranasp and Mircera that jagan now does with Procrit.

    • Good job jagan

 
AFFY
1.20-0.36(-23.08%)Jun 5 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.